| Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases A Cipponi, M Mercier, T Seremet, JF Baurain, I Théate, J van den Oord, ... Cancer research 72 (16), 3997-4007, 2012 | 253 | 2012 |
| Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 … M Schreuer, Y Jansen, S Planken, I Chevolet, T Seremet, V Kruse, ... The Lancet Oncology 18 (4), 464-472, 2017 | 211 | 2017 |
| Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma YJL Jansen, EA Rozeman, R Mason, SM Goldinger, MHG Foppen, ... Annals of Oncology 30 (7), 1154-1161, 2019 | 197 | 2019 |
| Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with … M Schreuer, G Meersseman, S Van Den Herrewegen, Y Jansen, ... Journal of translational medicine 14, 1-11, 2016 | 160 | 2016 |
| Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy T Seremet, Y Jansen, S Planken, H Njimi, M Delaunoy, H El Housni, ... Journal of translational medicine 17, 1-13, 2019 | 115 | 2019 |
| A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV … Y Jansen, V Kruse, J Corthals, K Schats, PJ van Dam, T Seremet, ... Cancer Immunology, Immunotherapy 69, 2589-2598, 2020 | 60 | 2020 |
| Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma N Sundahl, T Seremet, J Van Dorpe, B Neyns, L Ferdinande, A Meireson, ... International Journal of Radiation Oncology* Biology* Physics 104 (4), 828-835, 2019 | 55 | 2019 |
| Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction in genetically heterogeneous metastatic melanoma R Váraljai, K Wistuba-Hamprecht, T Seremet, JMS Diaz, J Nsengimana, ... JCO precision oncology 3, 1-10, 2019 | 49 | 2019 |
| Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy T Seremet, F Brasseur, PG Coulie The Cancer Journal 17 (5), 325-330, 2011 | 45 | 2011 |
| Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib YJ Jansen, P Janssens, A Hoorens, MS Schreuer, T Seremet, ... Melanoma Research 25 (6), 550-554, 2015 | 41 | 2015 |
| Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients T Seremet, A Koch, Y Jansen, M Schreuer, S Wilgenhof, V Del Marmol, ... Journal of translational medicine 14, 1-14, 2016 | 31 | 2016 |
| A comprehensive analysis of baseline clinical characteristics and biomarkers associated with outcome in advanced melanoma patients treated with pembrolizumab G Awada, Y Jansen, JK Schwarze, J Tijtgat, L Hellinckx, O Gondry, ... Cancers 13 (2), 168, 2021 | 28 | 2021 |
| Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases YJL Jansen, G Verset, K Schats, PJ Van Dam, T Seremet, M Kockx, ... ESMO open 4 (2), e000464, 2019 | 27 | 2019 |
| Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from … T Seremet, S Planken, M Schreuer, Y Jansen, M Delaunoy, H El Housni, ... Melanoma research 28 (1), 65-70, 2018 | 25 | 2018 |
| Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition G Awada, T Seremet, K Fostier, H Everaert, B Neyns Blood Advances 2 (16), 2156-2158, 2018 | 21 | 2018 |
| Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma M Schreuer, G Meersseman, S van Den Herrewegen, Y Jansen, ... Melanoma Research 26 (2), 157-163, 2016 | 20 | 2016 |
| The predictive and prognostic significance of cell‐free DNA concentration in melanoma R Váraljai, S Elouali, SS Lueong, K Wistuba‐Hamprecht, T Seremet, ... Journal of the European Academy of Dermatology and Venereology 35 (2), 387-395, 2021 | 18 | 2021 |
| Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma T Seremet, S Planken, JK Schwarze, Y Jansen, L Vandeweerd, ... Melanoma Research 29 (1), 85-88, 2019 | 18 | 2019 |
| Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial JK Schwarze, S Garaud, YJL Jansen, G Awada, V Vandersleyen, J Tijtgat, ... Cancers 14 (3), 682, 2022 | 12 | 2022 |
| Successful (neo) adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma T Seremet, D Lienard, M Suppa, AL Trepant, S Rorive, E Woff, N Cuylits, ... Melanoma research 25 (2), 180-183, 2015 | 12 | 2015 |
